EchoSolv AS vs Imbio PHA (4.0.0)
AI Verdict
Choose EchoSolv AS if…
Choose EchoSolv AS if your primary goal is to accurately and efficiently identify patients at high risk for severe aortic stenosis using existing echocardiogram measurements. This tool is ideal for cardiology departments seeking an AI-powered second reader to prioritize studies and streamline the diagnostic workflow for sAS, without requiring complex EMR integration.
View EchoSolv AS →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if you need automated, rapid assessment of cardiac structures from CT pulmonary angiogram (CTPA) scans to aid in the diagnosis and risk stratification of pulmonary embolism or hypertension. This tool is best suited for radiology and pulmonology departments looking to quantify right ventricular dilation and other key cardiac measurements from CTPA images.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | EchoSolv AS | Imbio PHA (4.0.0) |
|---|---|---|
| Deployment | Cloud-based | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
EchoSolv ASEchoSolv AS offers ultra-fast risk detection in under 3 seconds, significantly faster than Imbio PHA's typical assessment time of minutes. Its measurement-based AI, which analyzes numerical measurements rather than images, and its design to fit existing workflows without requiring EMR integration, may simplify data input and integration for users.
Clinical Value
EchoSolv ASBoth tools are FDA-cleared and provide valuable clinical insights. However, EchoSolv AS has demonstrated near-perfect accuracy in detecting severe AS, outperforming traditional clinical interpretation with specific sensitivity and specificity metrics. It also highlights its ability to identify high-risk patients who do not meet conventional guidelines, reducing missed diagnoses.
Pricing & Value
EchoSolv ASWhile neither tool provides direct pricing, EchoSolv AS has identified a clear reimbursement pathway via Miscellaneous Code 93799, with an expected reimbursement rate of US$100 to US$150 on a fee-per-use basis. This transparency and established reimbursement mechanism provide a tangible value proposition for healthcare providers, which Imbio PHA does not detail.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA offers more flexible deployment options, including Cloud, Enterprise (on-premise), or via partners, which caters to a broader range of IT infrastructure and data governance requirements in large enterprises. While EchoSolv AS is cloud-based and SOC 2 Type II certified, Imbio PHA's on-premise option provides greater adaptability for diverse enterprise environments.
Innovation
EchoSolv ASEchoSolv AS demonstrates a more distinct innovative approach by utilizing measurement-based AI that specifically 'does not use LVOT measurements' for severe aortic stenosis analysis. This methodology, coupled with its ability to identify high-risk patients missed by conventional guidelines, suggests a novel solution to a specific clinical challenge.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA provides readily accessible support documentation, including a user manual available online, and offers clear contact information for support via phone and email with specified operating hours. EchoSolv AS mentions a 'Trust Center' for security and compliance documentation, but less explicit detail on general product user manuals or comprehensive support channels.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | EchoSolv AS | Imbio PHA (4.0.0) |
|---|---|---|
| Name | EchoSolv AS | Imbio PHA (4.0.0) |
| Company | Echo IQ | Imbio |
| Primary Clinical Focus | Analyzes echocardiograms to identify patients at risk for severe aortic stenosis. | Measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess right ventricular dilation and aid in diagnosis and risk stratification of pulmonary embolism and hypertension. |
| Target Medical Specialties | Cardiology, Cardiothoracic Surgery | Cardiology, Pulmonology, Radiology |
| AI Input Data Type | Echocardiogram measurements (numerical measurements, not images) | CT pulmonary angiogram (CTPA) scans (medical images) |
| Key AI Functionality | AI-powered clinical decision support for severe aortic stenosis probability; consistent severe AS probability and guideline check from measurements; second reader support. | Automated measurement of right and left ventricle diameters, main pulmonary artery and aorta diameters; calculates RV/LV and PA/Ao ratios; anatomical identification and measurement. |
| Processing Speed | Under 3 seconds | Typically in minutes |
Videos
Demos, reviews, and walkthroughs featuring EchoSolv AS and Imbio PHA (4.0.0).